menu
    • menu

    Company profile for Renibus Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Rénibus Therapeutics Inc. (RTI) is a clinical-stage biotech company focused on the development of novel pharmacologic therapies for acute and chronic kidney disease. Acute Kidney Injury (AKI) remains a significant, unmet medical need with no approved treatment. Postoperative AKI occurs in approximately 30% of patients undergoing cardiac surgery and significantly increases the risk of death (Rosner 2006). Progression to chr...
    Rénibus Therapeutics Inc. (RTI) is a clinical-stage biotech company focused on the development of novel pharmacologic therapies for acute and chronic kidney disease. Acute Kidney Injury (AKI) remains a significant, unmet medical need with no approved treatment. Postoperative AKI occurs in approximately 30% of patients undergoing cardiac surgery and significantly increases the risk of death (Rosner 2006). Progression to chronic kidney disease (CKD) within 24 months occurs in approximately 15-20% of patients who survive AKI (Chawla 2012).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Renibus TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    181 Grand Ave, Suite 225, Southlake, TX 76092
    Telephone
    Telephone
    682-285-1711
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://renibus.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Grants Orphan Drug Tag to Veverimer for Anti-GBM
    FDA Grants Orphan Drug Tag to Veverimer for Anti-GBM

    10 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/renibus-therapeutics-announces-fda-orphan-drug-designation-for-veverimer-for-the-treatment-of-anti-glomerular-basement-membrane-disease-anti-gbm-302477669.html

    PR NEWSWIRE
    10 Jun 2025
    Share Share
    Renibus Therapeutics to Present RBT-1 Poster at SCA Meeting
    Renibus Therapeutics to Present RBT-1 Poster at SCA Meeting

    25 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/renibus-therapeutics-announces-poster-presentation-on-rbt-1-at-the-47th-annual-meeting-of-the-society-of-cardiovascular-anesthesiologists-sca-302438647.html

    PR NEWSWIRE
    25 Apr 2025
    Share Share
    Renibus Therapeutics Completes Enrollment in RBT-1 Trial
    Renibus Therapeutics Completes Enrollment in RBT-1 Trial

    24 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/renibus-therapeutics-announces-completion-of-enrollment-in-protect-a-pivotal-phase-3-clinical-trial-of-rbt-1-to-reduce-the-risk-of-post-operative-complications-after-cardiac-surgery-302436778.html

    PR NEWSWIRE
    24 Apr 2025
    Share Share
    Renibus to Present at Oppenheimer 35th Healthcare Conference
    Renibus to Present at Oppenheimer 35th Healthcare Conference

    05 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/renibus-to-present-at-oppenheimers-35th-annual-healthcare-life-sciences-conference-302369302.html

    PR NEWSWIRE
    05 Feb 2025
    Share Share
    Renibus Therapeutics Announces Participation at Investor Conferences
    Renibus Therapeutics Announces Participation at Investor Conferences

    24 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/renibus-therapeutics-announces-participation-at-upcoming-investor-conferences-302257550.html

    PR NEWSWIRE
    24 Sep 2024
    Share Share
    Renibus Announces Presentation at Oppenheimer 34th Annual Healthcare Conference
    Renibus Announces Presentation at Oppenheimer 34th Annual Healthcare Conference

    07 Feb 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/renibus-therapeutics-announces-presentation-at-oppenheimer-34th-annual-healthcare-conference-302055962.html

    PR NEWSWIRE
    07 Feb 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search